A Safety and Efficacy Study of Carbidopa-levodopa in Patients With Macular Degeneration

NCT02873351 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

INDIV

Sponsor class

Stopped Decided to do studies in patients with AMD

Conditions

Age-related Macular Degeneration

Interventions

DRUG: carbidopa-levodopa 25-100 mg
DRUG: placebo for carbidopa-levodopa 25-100 mg

Sponsor

Snyder, Robert W., M.D., Ph.D., P.C.